N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
(NASDAQ:NITO),(Frankfurt:80W), Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon […]